Sanofi Q1 Sales Climb 13.6% to €10.5B, Dupixent Nears €4.2B
Sanofi reported Q1 net sales of €10.5 billion, up 13.6%, driven by Dupixent’s nearly €4.2 billion and 42% growth in ALTUVIIIO to €325 million. The company maintained high-single-digit sales growth guidance for 2026 and plans to complete a €1 billion share buyback in coming days.
1. Q1 Sales and Earnings
Sanofi reported Q1 net sales of €10.5 billion, marking a 13.6% increase year-over-year, and business EPS grew 14% driven by robust top-line momentum. Operating expenses rose by 7%, causing a slight dip in BOI margin due to elevated profit sharing and capital gains phasing.
2. Product Performance
Blockbuster Dupixent approached €4.2 billion in sales, supported by new indications, while ALTUVIIIO posted a 42% jump to €325 million. Other key products included Beyfortus at €284 million, Sarclisa up 30% to €167 million, Ayvakit at €170 million, and Rare Disease sales near €1.8 billion.
3. Guidance and Share Buyback
Sanofi upheld its 2026 outlook for high single-digit sales growth at constant exchange rates and expects business EPS to outpace sales growth. The company will complete a €1 billion share buyback in the coming days to return capital to shareholders.